The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Cardiology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Fri, 09 Oct 2026 06:27:11 GMT 2026 NEJM Group en-us 1440 In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths. https://www.nejm.org/doi/full/10.1056/NEJMoa2606934?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 Jörg Hausleiter, Thomas J. Stocker, Tobias Geisler, Philipp Lurz, Wolfgang Rottbauer, Edith Lubos, Niklas Schofer, Christian Frerker, Johanne Frank, Holger Thiele, Rico Osteresch, Volker Rudolph, Alexander Lauten, Erion Xhepa, Jürgen Rothe, Tienush Rassaf, Stephan Baldus, Georg Nickenig, David M. Leistner, Eike Tigges, Victoria Kehl, Mirjam Kessler, Tobias Kister, Tobias Ruf, Muhammed Gerçek, Meinrad Gawaz, Derk Frank, Ingo Eitel, Ralph Stephan von Bardeleben, Daniel Kalbacher, Osama Soliman, Michael Näbauer, Steffen Massberg, the TRIC-I-HF-DZHK24 Investigators* 2026-10-08 Tricuspid-Valve Intervention in Heart Failure The care of patients with valvular heart disease has been revolutionized by three key advances in the field: technological innovation of transcatheter therapies combined with the audacity to try new procedures; a heart team that includes interventional cardiologists, cardiac surgeons, imaging specialists, and, when needed, heart-failure cardiologists working in partnership... https://www.nejm.org/doi/full/10.1056/NEJMe2611648?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2611648 Manesh R. Patel 2026-10-08 Transcatheter Tricuspid-Valve Intervention for Severe Tricuspid Regurgitation In five pediatric heart transplantations, a rapid-recovery technique involving oxygenated preservation enabled the use of donated hearts without reanimation. All recipients had normal biventricular function by day 7. https://www.nejm.org/doi/full/10.1056/NEJMc2607437?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2607437 Aaron M. Williams, Swaroop Bommareddi, Kevin C. McGann, Awab Ahmad, John Trahanas, Brian Lima, Tammy Ruth, David W. Bearl, Rachel E. Harris, Ryan D. Byrne, Caroline West, A. Joey Lepore, Phyllis Aycock, Nicole Michaud, Sonya Burrell, Susana A. Stripling, Amir T. Dereshgi, Garrett Coyan, David Bichell, Amanpreet Kalsi, Amy M. Babb, Michael Kuntz, Jessica Clark, Shelley Scholl, Matthew Bacchetta, Ashish S. Shah, Yishay Orr, Carlos M. Mery, Ziv Beckerman 2026-10-08 Pediatric Heart Transplantation with Donation after Circulatory Death In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival. https://www.nejm.org/doi/full/10.1056/NEJMoa2607314?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607314 Sophia Zoungas, Rory Wolfe, Chris Moran, Stephen J. Nicholls, Geoffrey C. Cloud, Christopher M. Reid, Andrew M. Τonkin, Lawrence Beilin, Anthony S. Wierzbicki, Trevor T.-J. Chong, Jonathan C. Broder, Andrea J. Curtis, Zachary Flanagan, Ingrid Hopper, Joanne Ryan, Simone Spark, John J. McNeil, Mark R. Nelson, the STAREE Investigators 2026-10-01 Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults For decades, one of the most important unresolved questions in preventive cardiovascular medicine has been whether statin therapy should be initiated for primary prevention in healthy older adults. Although age is among the strongest determinants of absolute risk, the benefits of statin therapy beyond 70 to 75 years of age... https://www.nejm.org/doi/full/10.1056/NEJMe2611127?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2611127 Martin Bødtker Mortensen 2026-10-01 Statins in Older Adults — Evidence at Last In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year. https://www.nejm.org/doi/full/10.1056/NEJMc2609825?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2609825 Luke J. Laffin, Stephen J. Nicholls, Russell S. Scott, Peter M. Clifton, Renate Koops, Ashish Sarraju, Shweta Singh, Qiuqing Wang, Kathy Wolski, Huansheng Xu, Jen Nielsen, Naimish Patel, Jason M. Duran, Steven E. Nissen 2026-10-01 Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. https://www.nejm.org/doi/full/10.1056/NEJMoa2601598?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601598 Yves Dauvilliers, Emmanuel Mignot, Jakub Antczak, Isabelle Arnulf, Lucie Barateau, Erik Buntinx, Bruce Corser, Alex Iranzo, Ramin Khatami, Gert Jan Lammers, Katharina Lederer, Kristian Bernhard Nilsen, Fabio Pizza, Markus H. Schmidt, Sheila Sivam, Oliver Sum-Ping, Mitsutaka Taniguchi, Shuqin Zhan, Anson Abraham, Alice Cai, Yeting Du, Mark R. Etherton, Helene Faessel, Samuel Hsiao, Harisha Kadali, Elena Koundourakis, Melissa Naylor, Rachel Neuwirth, Tina Olsson, Raquel Rogers, Sarah Sheikh, Shinichiro Tanaka, Philipp von Rosenstiel, Christian von Hehn, Yaming Hang, Baiyun Yao, Rafael del Rio Villegas, Giuseppe Plazzi 2026-09-24 Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. https://www.nejm.org/doi/full/10.1056/NEJMoa2607978?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607978 Daehoon Kim, Young Soo Lee, Jaemin Shim, Hee Tae Yu, Junbeom Park, Jin-Kyu Park, Il-Young Oh, Ki-Woon Kang, Eue-Keun Choi, Kyoung-Min Park, Hyoung-Seob Park, Dae-Hyeok Kim, Hyung Wook Park, Jun Kim, Jum-Suk Ko, Dongmin Kim, Jong-Youn Kim, Jin-Bae Kim, Jung-Hoon Sung, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Boyoung Joung, the SINGLE-AF Investigators* 2026-09-24 Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk Stroke is a severe and common complication of atrial fibrillation. Anticoagulation with vitamin K antagonists or with direct oral anticoagulants (DOACs) prevents the majority of strokes in patients with atrial fibrillation and at least two clinical risk factors for stroke (Table 1).1 Patients who receive DOACs or vitamin... https://www.nejm.org/doi/full/10.1056/NEJMe2610344?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2610344 Paulus Kirchhof 2026-09-24 Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke A 72-year-old man with hypertension, hyperlipidemia, and a stable ascending aortic aneurysm presented with sudden-onset, severe chest pain. CTA of the chest, abdomen, and pelvis showed a celiac-artery dissection. https://www.nejm.org/doi/full/10.1056/NEJMicm2605936?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2605936 Akshat Agrawal, Kimberly Foust 2026-09-17 Celiac-Artery Dissection Among patients with ST-segment elevation myocardial infarction and multivessel disease, physiology-guided angiography led to a lower risk of major cardiovascular events than conventional angiography-guided treatment. https://www.nejm.org/doi/full/10.1056/NEJMoa2605373?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605373 Simone Biscaglia, Andrea Erriquez, Iginio Colaiori, Abdul Hakeem, Francesca Mantovani, Mila Menozzi, Marco Barbierato, Manfredi Arioti, Giulia Bugani, Roberto Scarsini, Domenico D’Amario, Luca Donazzan, Alberto Polimeni, Massimo Giordan, Giorgio Benatti, Gabriele Venturi, Marco Ruozzi, Francesco Moretti, Alberto Monello, Elisabetta Moscarella, Francesco Versaci, Jehangir Ali Shah, Vincenzo Guiducci, Caterina Cavazza, Francesco Gallo, Andrea Rubboli, Marco Borgi, Ahsan Ali Lakho, Alessandro Capecchi, Valerio Lanzilotti, Filippo Ottani, Gianni Casella, Antonio Maria Leone, Matteo Tebaldi, Rita Pavasini, Raffaele Piccolo, Jacopo Farina, Donato Martella, Gianluca Campo, the AIR-STEMI Trial Investigators* 2026-09-10 Complete Revascularization Guided by Functional Coronary Angiography in STEMI Catheter-directed thrombolysis led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse at 7 days than anticoagulation alone in intermediate-high–risk acute pulmonary embolism. https://www.nejm.org/doi/full/10.1056/NEJMoa2608012?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2608012 Josef Kroupa, Martin Radvan, Jan Mrozek, Martin Sluka, Stepan Jirous, Ota Hlinomaz, Milan Pliva, Jan Pudil, Hana Voberkova, Karolina Bartoskova, Martin Poloczek, Martin Kamenik, Michal Brabec, Eva Lichnerova, Martin Hutyra, Ivo Bernat, Martin Novak, Johana Horakova, Lucie Jelinkova, Tomas Knize, Petr Tousek, Cyril Stechovsky, Filip Varhanik, Zdenek Coufal, Jiri Jarkovsky, Viktor Kocka 2026-08-31 Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care. https://www.nejm.org/doi/full/10.1056/NEJMoa2605812?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605812 Matthew J. Reed, Steve Goodacre, Christopher J. Weir, Lynn Dinsmore, Amy Nugent, Titouan Kennel, Christopher C. Lang, Neil R. Grubb, Praveen Thokala, Karen Kilcoyne, Rachel O’Brien, Caroline Blackstock, Shona McDonald, Nicola Freeman, Ellise Clarke, Imad Adamestam, Louise Taylor, the ASPIRED Investigators* 2026-08-31 Immediate Ambulatory Electrocardiographic Monitoring in Syncope In pulmonary hypertension associated with left heart disease and heart failure, pulmonary-artery denervation reduced clinical worsening and recurrent heart failure events as compared with guideline-directed medical therapy alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2609056?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609056 Hang Zhang, Qiguang Wang, Ming Liang, Xiang Chen, Wei Zhuang, Biao Cheng, Yue Li, Jieyan Shen, Bin Liu, Caojing Zhang, Gangcheng Zhang, Xinxue Liao, Zhenwen Yang, Ruilin He, Yuquan He, Yunshan Cao, Yan Wang, Dajun Chai, Wei Huang, Xiaoping Peng, Wen Gu, Gregg W. Stone, Yaling Han, Shao-Liang Chen, the PADN-HF-PH Investigators* 2026-08-30 Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension In patients with severe aortic stenosis and coronary artery disease, a strategy of transcatheter aortic-valve implantation before percutaneous coronary intervention was noninferior to PCI before TAVI for major clinical events at 1 year. https://www.nejm.org/doi/full/10.1056/NEJMoa2606924?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606924 Barbara E. Stähli, Frank Ruschitzka, Dirk Westermann, Axel Linke, Norman Mangner, Nicolas M. Van Mieghem, Rahel Kesterke, Laura Oberholzer, Jürgen Rothe, Constantin von zur Mühlen, Tobias Zeus, Won-Keun Kim, Philipp Lauten, Nikos Werner, Christof Burgdorf, Hannes Alber, P. Christian Schulze, Michael Joner, Jonathan Michel, Alessandro Candreva, Philipp Jakob, Michael Würdinger, Julia Stehli, Alexander Gotschy, Christian Templin, Omer Dzemali, Luise Gaede, Steffen Massberg, Alexander Lauten, Frank van der Kley, Aydan Ewers, Thomas Nestelberger, Mohamed Abdel-Wahab, Giuseppe Musumeci, Sebastian Barth, Michael Hansen, Andreas Mügge, Moritz Seiffert, David M. Leistner, Thomas Cuisset, Steffen Schneider, Adnan Kastrati, Ian Ford, Markus A. Kasel, the TAVI PCI Investigators* 2026-08-30 Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2608717?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2608717 C. Michael Gibson, P. Gabriel Steg, M. Cecilia Bahit, Rasha Al-Lamee, Shamir R. Mehta, Roxana Mehran, Jeffrey I. Weitz, Shinya Goto, Jose Carlos Nicolau, Renato D. Lopes, Junbo Ge, Nebojsa Tasic, Dominick J. Angiolillo, Suzanne J. Baron, Ajay J. Kirtane, Denis Xavier, Satoshi Yasuda, Basil S. Lewis, Duk-Woo Park, Jan H. Cornel, Thomas W. Johnson, Jaroslaw Trebacz, Daniel Duerschmied, Christoph Bode, Bela Merkely, Maria Dorobantu, Dragos Vinereanu, Zuzana Motovska, Hector Bueno, Jose Luis Lopez-Sendon, Gregory Ducrocq, Giuseppe Ambrosio, Lesley Burgess, Allan Bohm, Chern-En Chiang, Joao Morais, Alan Fong, Umit Guray, Jose Luis Leiva-Pons, Pascal Vranckx, Harvey D. White, Sasko Kedev, Marco Valgimigli, Duško Cerovec, Dimitris Tousoulis, Gemma Figtree, Thuong Dung Ho, Rody G. Sy, Morten Bøttcher, Kurt Huber, Rimvydas Slapikas, Andrejs Erglis, Jack Wei Chieh Tan, Christian Pincetti, Karen S. Pieper, Kenneth W. Mahaffey, Carolyn S.P. Lam, S. Claiborne Johnston, Graeme J. Hankey, Jennifer S. Li, Luke Zheng, Ronald Aronson, Danshi Li, Ravi Notani, Philippe Vieira Pires, Thomas J. Povsic, Alistair C. Lindsay, Alexei Plotnikov, Hsiaowei Deng, Elliot S. Barnathan, Robert A. Harrington, the LIBREXIA ACS Committees and Investigators* 2026-08-29 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event In patients at high risk for ischemic events 12 months after implantation of a drug-eluting stent, clopidogrel monotherapy was noninferior to extended dual antiplatelet therapy for net adverse clinical events. https://www.nejm.org/doi/full/10.1056/NEJMoa2608533?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2608533 Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee, Deok-Kyu Cho, Yun-Hyeong Cho, Sung Gyun Ahn, Kyeong Ho Yun, Ji-Yong Jang, Seunghwan Kim, Yong Hoon Kim, Yong Hwan Park, Sung Uk Kwon, Seung-Ho Hur, Tae Soo Kang, Eun-Seok Shin, Jin Bae Lee, Ki-Hyun Jeon, Ung Kim, Won Ho Kim, Bum-Kee Hong, Sang-Hyup Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Byeong-Keuk Kim, the A-CLOSE investigators* 2026-08-29 Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months. https://www.nejm.org/doi/full/10.1056/NEJMoa2606997?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606997 Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino, Kosuke Kashiwabara, Hiromasa Otake, Satoru Suwa, Mamoru Nanasato, Takashi Muramatsu, Hitoshi Anzai, Akihiro Shirakabe, Masashi Yamamoto, Yasuhide Asaumi, Masashi Sakuma, Hideki Okayama, Keisuke Nakabayashi, Nobuhiko Ogata, Kentaro Jujo, Kohei Wakabayashi, Takanori Kusuyama, Yuko Onishi, Kazuhiro Ashida, Yuya Mitsuhashi, Yuji Nishimoto, Seiji Yamazaki, Nehiro Kuriyama, Yuji Ikari, Gaku Nakazawa, the PREMIUM Trial Investigators* 2026-08-29 Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI Among patients with acute coronary syndromes undergoing percutaneous coronary intervention, the risk of ischemic events was not lower with a default prasugrel policy than with a default ticagrelor policy. https://www.nejm.org/doi/full/10.1056/NEJMoa2609057?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609057 Elmir Omerovic, Sasha Koul, Jonas Andersson, Johan Pontén, Fredrik Björklund, Robert Kastberg, Mila Sun, Charlotta Ljungman, Ole Fröbert, Kristian Bolin, Kristofer Skoglund, Carl-David Dolata, Mats Birgander, Helena Wikström, Truls Råmunddal, Oskar Angerås, Petur Petursson, David Erlinge, Björn Redfors 2026-08-29 Prasugrel versus Ticagrelor in Acute Coronary Syndromes Among 16,808 adults without known cardiovascular disease, silent atherosclerosis was present in 57.1%, was detectable in early adulthood, and became more prevalent and extensive with age in a sex-dependent pattern. https://www.nejm.org/doi/full/10.1056/NEJMoa2609059?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609059 Henning Bundgaard, Inés García-Lunar, Klaus F. Kofoed, Rasmus Hasselbalch, Carlos Nicolás Pérez-García, Joakim Bo Kunkel, Frederik Filip Stæger, Fátima Sánchez-Cabo, José J. Fuster, Virginia Mass, Javier Sánchez-González, Maja V. Kragh, Anna K. Ringgaard, Javier Valls-Monzó, Michael Huy Cuong Pham, Ana Devesa, Morten Sejer, Per Sigvardsen, Antonio Quesada, Charlotte Eberhard, Ana García-Álvarez, Lea Marie Pehrson, Álvaro Navarro-Guzmán, Simon Winther, Mathias Sørgaard, Marcos Gámez, Martin Lundsgaard, Cristina Pérez-Herreras, Ruth Frikke-Schmidt, Pedro L. Sánchez, Nikolaj Eldrup, Juan Torres-Macho, Morten Bøttcher, Valentin Fuster, Kasper K. Iversen, Borja Ibanez, the REACT Investigators* 2026-08-29 Prevalence of Silent Atherosclerosis across Adult Life